Viridian Therapeutics (VRDN) Stock Price, News & Analysis

Company Overview

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes.

The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration. These candidates remain investigational.

Viridian’s roots include Miragen Therapeutics, which adopted the Viridian Therapeutics name in 2021. The company conducts clinical development to evaluate its potential treatments; its candidates are not approved medicines.

Key Stats

• Today's Range: $29.81 to $30.96
• 50-Day Range: $18.22 to $31.25
• 52-Week Range: $13.18 to $34.29
• Volume: 1.20 million shs
• Average Volume: 2.95 million shs
• Market Capitalization: $3.51 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.00
• Consensus Rating: Moderate Buy

Viridian Therapeutics Stock Analysis - MarketRank™

Viridian Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 199th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Viridian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 11 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Viridian Therapeutics has a consensus price target of $41.00, representing about 32.8% upside from its current price of $30.87.

Amount of Analyst Coverage

Viridian Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Viridian Therapeutics are expected to grow in the coming year, from ($3.64) to ($2.13) per share.

Price to Book Value per Share Ratio

Viridian Therapeutics has a P/B Ratio of 7.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

15.38% of the float of Viridian Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Viridian Therapeutics has a short interest ratio ("days to cover") of 9.07.

Change versus previous month

Short interest in Viridian Therapeutics has recently decreased by 5.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Viridian Therapeutics does not currently pay a dividend.

Dividend Growth

Viridian Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.82

News Sentiment

Viridian Therapeutics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 25 news articles for Viridian Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for VRDN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Viridian Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Viridian Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $348,194.00 in company stock.

Percentage Held by Insiders

2.40% of the stock of Viridian Therapeutics is held by insiders.

Percentage Held by Institutions

Viridian Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 11/04/2026
• Today: 11/13/2026
• Jefferies Global Healthcare Conference: 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VRDN
• CIK: 1590750
• Web: www.viridiantherapeutics.com
• Phone: (617) 272-4600
• Fax: 760-537-4101
• Employees: 252
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Viridian Therapeutics: $41.00
• High Price Target: $54.00
• Low Price Target: $26.00
• Potential Upside/Downside: +32.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$342.60 million
• Net Margins: -1,620.79%
• Pretax Margin: -1,724.06%
• Return on Equity: -79.67%
• Return on Assets: -44.72%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 14.46
• Quick Ratio: 14.46

Sales & Book Value

• Annual Sales: $70.85 million
• Price / Sales: 49.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.25 per share
• Price / Book: 7.26

Miscellaneous

• Outstanding Shares: 113,560,000
• Free Float: 110,833,000
• Market Cap: $3.51 billion
• Optionable: Optionable
• Beta: 1.07